icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
DVzrnqmcYBPgkGuB